Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3990957 | Journal of Thoracic Oncology | 2011 | 7 Pages |
Abstract
Although the S-1 + cisplatin regimen used in this study appeared to have a similar level of antitumor activity and toxicity to that of established cisplatin-based doublets in NSCLC, the protocol-specified criteria of sufficient efficacy to warrant further study with an objective response rate â¥30% was not achieved. Therefore, while S-1 appears to be a promising agent in NSCLC, further evaluation should be conducted to determine the optimal S-1-based regimen to take forward for additional study.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alan MD, Charles MD, Maria MD, Roy MD, PhD, Christopher BS, Kaku MS, Dennie MD,